Linagliptin safety profile: A systematic review.
作者： Gabrielle Kéfrem Alves Gomes , Aline Istéfane de Camargos Ramos , Camila Tavares de Sousa , Cristina Sanches , Mariana Linhares Pereira
DOI: 10.1016/J.PCD.2018.04.006
关键词:
摘要: Abstract Objective To describe the safety profile of linagliptin. Methodology Systematic review using PubMed/MEDLINE, BVS and Web Science. The search strategy “Linagliptin” AND “safety” was used. inclusion criteria were clinical trials with a control group composed conventional DM2 pharmacotherapy. Results We identified 16 studies, most frequent adverse events (AEs) nasopharyngitis linagliptin at 5 10 mg in monotherapy (31.6% 29.6%, respectively) gastrointestinal (>10.0%) combination. Of AEs, 14.9 (±3.1)% associated use monotherapy, 17.6 (±6.0)% AEs have varied occurrence frequency, ranging from mild to moderate intensity.
sci-hub.se 参考文章(37)
Yun-Zhao Tang, Gang Wang, Zhen-Huan Jiang, Tian-Tian Yan, Yi-Jun Chen, Min Yang, Ling-Ling Meng, Yan-Juan Zhu, Chen-Guang Li, Zhu Li, Ping Yu, Chang-Lin Ni, Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent Diabetology & Metabolic Syndrome. ,vol. 7, pp. 91- 91 ,(2015) , 10.1186/S13098-015-0087-3
R. Gomis, D. R. Owens, M.-R. Taskinen, S. Del Prato, S. Patel, A. Pivovarova, A. Schlosser, H.-J. Woerle, Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24-week phase III trials followed by a 78-week open-label extension. International Journal of Clinical Practice. ,vol. 66, pp. 731- 740 ,(2012) , 10.1111/J.1742-1241.2012.02975.X
T. Vilsbøll, J. J. Holst, Incretins, insulin secretion and Type 2 diabetes mellitus Diabetologia. ,vol. 47, pp. 357- 366 ,(2004) , 10.1007/S00125-004-1342-6
Vaishali Deshmukh, Srikanta Sathyanarayana, Shalini Menon, Shiva Patil, Russel Jones, Shweta Uppal, Kamran Siddiqui, Safety and efficacy of initial combination of linagliptin and metformin in patients with type 2 diabetes: A subgroup analysis of Indian patients from a randomized, double-blind, placebo-controlled study Indian Journal of Endocrinology and Metabolism. ,vol. 19, pp. 256- 261 ,(2015) , 10.4103/2230-8210.149319
S. A. Ross, A. E. Caballero, S. Del Prato, B. Gallwitz, D. Lewis‐D'Agostino, Z. Bailes, S. Thiemann, S. Patel, H.‐J. Woerle, M. von Eynatten, Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double-blind, active-controlled, parallel group, multinational clinical trial. Diabetes, Obesity and Metabolism. ,vol. 17, pp. 136- 144 ,(2015) , 10.1111/DOM.12399
KG Seshadri, MHB Kirubha, Gliptins: a new class of oral antidiabetic agents Indian Journal of Pharmaceutical Sciences. ,vol. 71, pp. 608- 614 ,(2009) , 10.4103/0250-474X.59541
Maria Angela Sortino, Tiziana Sinagra, Pier Luigi Canonico, Linagliptin: A thorough Characterization beyond Its Clinical Efficacy. Frontiers in Endocrinology. ,vol. 4, pp. 16- 16 ,(2013) , 10.3389/FENDO.2013.00016
André J Scheen, Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opinion on Drug Safety. ,vol. 14, pp. 505- 524 ,(2015) , 10.1517/14740338.2015.1006625
N. Inagaki, H. Watada, M. Murai, T. Kagimura, Y. Gong, S. Patel, H.-J. Woerle, Linagliptin provides effective, well-tolerated add-on therapy to pre-existing oral antidiabetic therapy over 1 year in Japanese patients with type 2 diabetes Diabetes, Obesity and Metabolism. ,vol. 15, pp. 833- 843 ,(2013) , 10.1111/DOM.12110
Berthold Hocher, Karoline von Websky, Christoph Reichetzeder, Linagliptin as add-on therapy to insulin for patients with type 2 diabetes Vascular Health and Risk Management. ,vol. 9, pp. 681- 694 ,(2013) , 10.2147/VHRM.S40035